FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 633 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... September 23, 2025 ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to... April 1, 2022 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 How serendipity sent this oncologist in search of a cure for... August 12, 2022 Load more HOT NEWS Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and... Women Experience More Side Effects from Pelvic Radiation than Realized
